Christina Brennan of the Feinstein Institutes appointed to the Board of Directors of the Association of Clinical Research Professionals | Business


MANHASSET, NY – (BUSINESS WIRE) – January 7, 2022–

Christina Brennan, MD, MBA, vice president of clinical research at the Feinstein Institutes for Medical Research at Northwell Health, was elected by members of the Association of Clinical Research Professionals (ACRP) to serve on its board of directors for a second term.

This press release features multimedia. View the full release here:

Christina Brennan, MD, MBA is vice president of clinical research at the Feinstein Institutes for Medical Research. (Photo: Business Wire)

“Especially in these times of constant change and focus on clinical research, it is an honor to be re-elected to the CAPR Board of Directors,” said Dr. Brennan. “As a member, I support the mission of CRPA and hope to contribute to the future success of the organization and the future of clinical researchers.

CAPR is a Washington, DC-based, non-profit organization that supports clinical research professionals and provides tools to its 13,000 members through e-learning to develop their skills and improve their operations. Beyond webinars and other clinical development programs for researchers – dealing with regulatory developments, industry trends and best practices – CRPA also serves as a career resource for employment opportunities and maintains a community. online to connect with peers. Dr Brennan is the outgoing chair of the New York Metropolitan Chapter of CRPA and is an active member of the Clinical Trials Transformation Initiative with Duke University and the United States Food and Drug Administration.

Throughout the 2019 coronavirus disease (COVID-19) pandemic, Dr. Brennan has led nearly 20 clinical trials and projects launched across the healthcare system, which have recruited more than 1,900 participants. From potential over-the-counter therapies to studying industry-sponsored treatments and vaccine booster clinical trials, these COVID-19 trials have added valuable information and contributed to scientific findings around the world in the fight against course to prevent and treat the virus.

“The COVID-19 pandemic has issued a clear and present call to action for the global community to optimize and maintain the capacity of the clinical trial infrastructure,” said Kevin J. Tracey, MD, president and chief executive officer. the management of the Feinstein institutes. “By leading the COVID-19 clinical trials at Northwell Health, Dr. Brennan has demonstrated what leadership excellence can accomplish during a pandemic. She is a valuable asset to the CRPA.

Dr Brennan also serves on the Oncology Advisory Board of the Society for Clinical Research Sites and is a member of the American College of Healthcare Executives. She is the author of numerous textbook chapters, co-author of over 25 manuscripts and abstracts. Dr. Brennan is an Assistant Professor at Yeshiva University, where she teaches a course in Clinical Trials and Research Management for the Masters of Science, Biotechnology and Entrepreneurship program.

In 2021, Dr Brennan was introduced to the ACRP North Texas chapter at a special event around long-haul COVID-19 and a Novartis meeting to discuss diversity in clinical trials. In 2022, Dr Brennan is expected to speak at the Critical Research as a Care Option conference.

For more information on Feinstein Institutes clinical trials, click here.

About the Feinstein institutes

The Feinstein Institutes for Medical ResearchHome to the research institutes of Northwell Health, New York State’s largest healthcare provider and private employer. Encompassing 50 research laboratories, 3,000 clinical research studies and 5,000 researchers and employees, the Feinstein Institutes are raising the level of medical innovation through its five institutes of behavioral sciences, bioelectronic medicine, cancer, human sciences. health and molecular medicine systems. We are making breakthroughs in genetics, oncology, brain research, mental health, autoimmunity and are the global scientific leader in bioelectronic medicine, a new field of science that has the potential to revolutionize medicine. For more information on how we generate knowledge to cure disease, visit and follow us on LinkedIn.

See the source version on

CONTACT: Matthieu Libassi




SOURCE: Feinstein Institutes for Medical Research

Copyright Business Wire 2022.

PUB: 07/01/2022 9:00 a.m. / DISC: 07/01/2022 09:02 a.m.

Copyright Business Wire 2022.


About Author

Comments are closed.